Sugi Predict

Sugi Predict / Compounds / SCHEMBL4708399

SCHEMBL4708399

SCHEMBL4708399

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(=O)OC)cc(C(F)(F)F)c3)cc2)ccn1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 7/20 0.73
▸ MAPK14 Q16539 5/20 0.73
▸ RET P07949 4/20 0.73
▸ AURKB Q96GD4 3/20 0.73
▸ SRC P12931 3/20 0.73
▸ ABL1 P00519 3/20 0.73
▸ EPHA2 P29317 3/20 0.73
▸ MAP3K20 Q9NYL2 3/20 0.73
▸ PLK4 O00444 2/20 0.73
▸ AURKA O14965 2/20 0.73
▸ MAPK13 O15264 2/20 0.73
▸ MAP4K4 O95819 2/20 0.73
▸ LCK P06239 2/20 0.73
▸ FYN P06241 2/20 0.73
▸ LYN P07948 2/20 0.73
▸ RPS6KB1 P23443 2/20 0.73
▸ AXL P30530 2/20 0.73
▸ FRK P42685 2/20 0.73
▸ MAPK9 P45984 2/20 0.73
▸ BLK P51451 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16628056 0.91 KDR (0.83) KDRMAPK14RETAURKBSRC
SCHEMBL21124965 0.88 KDR (0.77) KDRMAPK14RETAURKBSRC
SCHEMBL12627795 0.88 KDR (0.69) KDRMAPK14RETAURKBSRC
SCHEMBL16628087 0.87 KDR (0.83) KDRMAPK14RETAURKBSRC
SCHEMBL14453668 0.87 KDR (0.76) KDRMAPK14RETAURKBSRC
SCHEMBL28430251 0.86 RAF1 (0.78) KDRMAPK14RETAURKBSRC
SCHEMBL14684305 0.85 KDR (0.83) KDRMAPK14RETAURKBSRC
SCHEMBL4708594 0.85 KDR (0.67) KDRMAPK14RETAURKBSRC
SCHEMBL16628085 0.85 KDR (1.00) KDRMAPK14RETAURKBSRC
SCHEMBL12627790 0.84 KDR (0.72) KDRMAPK14RETAURKBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973408-A2 INHIBITORS OF PROTEIN KINASES Locus Pharmaceuticals, Inc. (US) 2008-10-01 — — EP claimed
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 — — US claimed
WO-2007081690-A2 INHIBITORS OF PROTEIN KINASES LOCUS PHARMACEUTICALS, INC. (US) 2007-07-19 — — WO claimed
EP-1973408-A2 INHIBITORS OF PROTEIN KINASES Locus Pharmaceuticals, Inc. (US) 2008-10-01 — — EP disclosed
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 — — US disclosed
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 — — US disclosed
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 — — US disclosed
WO-2007081690-A2 INHIBITORS OF PROTEIN KINASES LOCUS PHARMACEUTICALS, INC. (US) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185098-A1 Inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K19 KDR 960/4885MAPK14 300/4885RET 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.